7/23/2019 Titan Medical Corporate Presentation.
http://slidepdf.com/reader/full/titan-medical-corporate-presentation 1/18
1
Titan Medical Inc.
Corporate Presentation
TSX: TMD | OTCQX: TITXF
November 24, 2015
7/23/2019 Titan Medical Corporate Presentation.
http://slidepdf.com/reader/full/titan-medical-corporate-presentation 2/18
2
This presentation contains "forward-looking statements" which reflect the current expectations of
management of the Company's future growth, results of operations, technological development and
implementation, performance and business prospects, opportunities, and illustrations and prototypes of the
SPORT™ Surgical Systems. Wherever possible, words such as "may", "would", "could", "will", "anticipate",
"believe", "plan", "expect", "intend", "estimate" and similar expressions have been used to identify these
forward-looking statements. These statements reflect management's current beliefs with respect to future
events and are based on information currently available to management. Forward-looking statements involve
significant risks, uncertainties and assumptions. Many factors could cause the Company's actual results,
performance, achievements or technological development and implementation to be materially different from
any future results, performance, achievements or technological development and implementation that may beexpressed or implied by such forward-looking statements, including, without limitation, those listed in the "Risk
Factors" section of the Company's Annual Information Form dated March 31, 2015 and other information
contained in the Company’s public filings (which may be viewed at www.sedar.com). Information contained in
this presentation is qualified in its entirety by such public filings. Should one or more of these risks or
uncertainties materialize, or should assumptions underlying the forward looking statements prove incorrect,
actual results, performance or achievements may vary materially from those expressed or implied by the
forward-looking statements contained in this presentation. These factors should be considered carefully andprospective investors should not place undue reliance on the forward-looking statements. Although the
forward-looking statements contained in the presentation are based upon what management currently
believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results,
performance or achievements will be consistent with these forward-looking statements. This presentation
does not constitute an offer to sell any class of securities of the Company in any jurisdiction.
Forward Looking Statements
7/23/2019 Titan Medical Corporate Presentation.
http://slidepdf.com/reader/full/titan-medical-corporate-presentation 3/18
3
Titan’s SPORT™ Surgical System
Artist/CAD Rendering of SPORT™ Surgical System*The SPORT™ Surgical System has not been approved for sale or use by any regulatory authority, including the FDA.
7/23/2019 Titan Medical Corporate Presentation.
http://slidepdf.com/reader/full/titan-medical-corporate-presentation 4/18
4
• Focused on meeting the Customers’ Needs inRobotic Surgery
– Capital cost – too expensive
– Cost per case – too high
– Lack of mobility reduces operational efficiency
– Return on investment – not realized in many programs
• Efficiency – color coding instruments, etc.
– Training programs need improvement
– Customer support and service
• Data collection and analytics
Titan Strategy
7/23/2019 Titan Medical Corporate Presentation.
http://slidepdf.com/reader/full/titan-medical-corporate-presentation 5/18
5
• The SPORT™ Surgical System delivers next generation
computer-assisted robotic surgical technology thatbuilds on traditional robotic surgical features:
– Tele-operation
– 3D stereoscopic imaging
– Restoration of instinctive control
• The SPORT™ Surgical System is designed to provide:
– An advanced workstation incorporating a 3D high definitiondisplay providing a more ergonomic friendly user interface
– Improved instrument dexterity
– Single incision access
The SPORT™ Surgical System
7/23/2019 Titan Medical Corporate Presentation.
http://slidepdf.com/reader/full/titan-medical-corporate-presentation 6/18
6
Two Main Components:
SPORT™ Surgical System CAD Rendering
Patient CartSurgeon Workstation
The SPORT™ Surgical System
7/23/2019 Titan Medical Corporate Presentation.
http://slidepdf.com/reader/full/titan-medical-corporate-presentation 7/187
Surgeon Workstation
SPORT™ Surgical System
Workstation CAD Rendering
• Advanced ergonomic surgeon interface
to allow the surgeon to more comfortablycontrol the surgical platform.
– The system adapts to the surgeon insteadof having the surgeon adapt to the system
• Enhanced Functionality/Features: – 3D high definition flat panel display
– Custom designed master controllers
– Second display for delivering ancillaryinformation
– Data collection and analytics
7/23/2019 Titan Medical Corporate Presentation.
http://slidepdf.com/reader/full/titan-medical-corporate-presentation 8/188
• Designed for optimal configurability for a variety ofsurgical indications and to be maneuvered aroundoperating room and surgical centers
• Incorporates an Insertion Tube for insertion into apatient during a surgical procedure, including:
– A stereoscopiccamera module
– Insertable roboticinstruments
Robotic Platform/Patient Cart
SPORT™ Surgical System Patient Cart CAD Rendering
7/23/2019 Titan Medical Corporate Presentation.
http://slidepdf.com/reader/full/titan-medical-corporate-presentation 9/189
Camera Module and Instruments
• Stereoscopic Camera Module
• Custom design allows a 19 mm diameterInsertion Tube enabling an incision size ofapproximately 25 mm
• Multi-direction movement
• Collapsible/Expandable
• Pan and Tilt
• Digital Zoom
• Robotic Instrument Arms• Multi-articulating to allow
for “snake-like” movement
• Single-patient use tool tips
7/23/2019 Titan Medical Corporate Presentation.
http://slidepdf.com/reader/full/titan-medical-corporate-presentation 10/1810
• Single-Patient Use Tool Tips – Sterile
– No Reprocessing Required
– First Use Quality Every Case
• Reposable Robotic Instruments
– More use cases for eachinstrument arm
– Reduces per case cost
SPORT™ Tools
7/23/2019 Titan Medical Corporate Presentation.
http://slidepdf.com/reader/full/titan-medical-corporate-presentation 11/18
11
Training Curriculum
Cognitive pre-training Knowledge Acquisition
Psychomotor skills training Technical Skills Acquisition
Team training Choreography & Communication
Troubleshooting Crisis Mitigation
Overview of safety Optimal Skills and Teamwork
Post-Training Assessment
Design assessment tools
Define: skills, setting, scoring
method, scenarios, & train
raters
Validate assessment toolsConstruct Validity, Predictive
Validity
Learning Experiences
Assessment Tools
SPORT™ Training & Assessment
• Training curriculum and and post-training assessmentprograms under development with the James and Sylvia Earl,Simulation to Advance Innovation and Learning (SAIL) Centerat Anne Arundel Medical Center (AAMC) in Annapolis, MD
7/23/2019 Titan Medical Corporate Presentation.
http://slidepdf.com/reader/full/titan-medical-corporate-presentation 12/18
12
• FDA:
– July 2015: Participated in Open Workshop on Robotic Assisted Devices sponsored by the FDA
– September 2015: Engaged a Contract ResearchOrganization (CRO) to implement Early Feasibility
Human Study – What’s Next (Anticipated): Q3 2016 Pivotal Human
Clinical Trial commenced
• CE Mark:
– July 2015: Contracted with a Notified Body
– What’s Next (Anticipated): Q2 2016 - Audit for CE Markapproval commenced
Regulatory
7/23/2019 Titan Medical Corporate Presentation.
http://slidepdf.com/reader/full/titan-medical-corporate-presentation 13/18
13
Intellectual Property
Patents: What Titan has today*
11 Patents from Technology Developed Internally or Exclusively Licensed
• Laparoscopic Surgery Generally – Use of Magnetics
• Robotic Surgery Instruments
• Robotic Surgery Input Control
• Laparoscopic Surgical Stapler
Patent Applications: What Titan has in the pipeline*
21 Patent Applications from Technology Developed Internally or Exclusively Licensed
• Robotic Surgery Instruments
• Robotic Surgery Input Control
• Robotic Surgery Control Systems andIntelligence
• Robotic Surgery Patient Cart
• Robotic Surgery Access
• Laparoscopic Surgical Stapler
*As of November 24, 2015
7/23/2019 Titan Medical Corporate Presentation.
http://slidepdf.com/reader/full/titan-medical-corporate-presentation 14/18
14
Development Milestones Estimated Cost(in U.S. $)
Schedule forMilestone
Completion
Comments
Alpha commercial prototype design complete(Design of prototype suitable for ongoing tissuetesting)
- Q1 2014 Completed
Alpha commercial prototype built - Q2 2014 Completed
Tissue testing(Testing performance of individual features andfunctionality)
- Q2 2014 Completed
Design and test of feasibility prototype complete(Demonstrate feasibility for next generation
console and advanced instruments)
- Q1 2015 Completed
Units built and ready for engineering verification(Prototype is formally tested to meet previouslydefined specifications)
Build 2 engineering verification units
Build 5 first in-human units
(2 milestones)
$14 million
$9 million
Q4 2015
Expected
Q1 2016
Expected
Development Milestones
7/23/2019 Titan Medical Corporate Presentation.
http://slidepdf.com/reader/full/titan-medical-corporate-presentation 15/18
15
Development Milestones Estimated Cost(in U.S. $)
Schedule forMilestone
Completion
Comments
Development Milestones – Cont’d
Early human feasibility report complete(Human clinical cases utilizing units are testedunder engineering verification)
$24 million
(2 milestones)
Q2 2016
Expected
First in human studiesconfirm capabilities of
SPORT™ Surgical System
for expanded use.
Build 4 additional humanclinical trial units.
Audit for CE Mark approval commenced Q2 2016
Expected
Pivotal human clinical trial commenced $5 million Q3 2016
Expected
Pivotal human clinical trial completed and510(k) application submitted to FDA
$5 million
(3 milestones)
Q4 2016
Expected
Outside U.S. commercial launch(Pending CE Mark approval)
Q4 2016
Expected
U.S. commercial launch
(Pending 510(k) market clearance)
Mid-2017
Expected
TOTAL U.S. $57 million
7/23/2019 Titan Medical Corporate Presentation.
http://slidepdf.com/reader/full/titan-medical-corporate-presentation 16/18
16
*Fully diluted includes, under the Treasury Stock method, an additional 2,775,151 options with a weighted-average exercise price of
CDN $1.32, as well as common shares issued as result of the public offering, November 16, 2015 and the private placement of
November 23, 2015.
In addition, 3,665,900 warrants (@CDN $1.85 expiring December 10, 2015), 5,121,500 warrants (@CDN $2.00 expiring June 21,
2016), 3,484,500 warrants (@CDN $1.75 expiring December 22, 2016), 390,729 warrants (@CDN $1.77 expiring March 14, 2017),
5,260,705 warrants (@CDN $1.25 expiring March 13, 2018), 8,317,856 warrants (@CDN $2.00 expiring February 19, 2017),
12,346,914 warrants (@CDN $2.75 expiring April 23, 2017) and an additional 7,012,195 warrants (@CDN $1.60 expiring November
16, 2020).
Financial Snapshot
TMD (TSX), TITXF (OTCQX)
(in US Dollars except warrants
and options exercisable in
Canadian dollars)
September 30, 2015
Share Price (TMD) $1.36
Cash, cash equivalents andshort-term investments
$10.1 million
Shares outstanding 116.5 million (117.4 millionFD*)
Market value 158.4 million ($159.7 millionFD*)
Management ownership(September 30, 2015)
6.18%
7/23/2019 Titan Medical Corporate Presentation.
http://slidepdf.com/reader/full/titan-medical-corporate-presentation 17/18
17
Stock Performance - TSX
$0.00
$50.00
$100.00
$150.00
$200.00
$250.00
$300.00
$350.00
$400.00
2009 2010 2011 2012 2013 2014
Titan Medical Inc. - Common Share Price Performance
Titan Medical Inc.
S&P/TSX Composite Index
As at December 31
31-Dec-09 31-Dec-10 31-Dec-11 31-Dec-12 31-Dec-13 31-Dec-14
Titan Medical Inc. 100.00 355.00 337.50 300.00 237.50 350.00
S&P/TSX Composite Index 100.00 114.45 101.78 105.85 115.97 124.57
The following table shows the value of CDN$100 invested in Common Shares on December 31, 2009 compared to CDN$100 invested inthe S&P/TSX Composite Index*:*All amounts in Canadian $.
7/23/2019 Titan Medical Corporate Presentation.
http://slidepdf.com/reader/full/titan-medical-corporate-presentation 18/18
18
Stock Ranking – OTCQX 2014
The 2015 OTCQX®
Best 50 is a rank ing of top per fo rming companies on theOTCQX Best Marketplace in 2014 based on one-year share price performanceand average daily dollar volume growth.
Source: http://www.otcmarkets.com/content/doc/2015-OTCQX-Best-50.pdf